The inquiry follows a series of clinical setbacks for the biopharmaceutical company’s flagship Duchenne muscular dystrophy therapy. Between March and July 2025, Sarepta reported three separate fatalities among patients treated with the gene therapy. Despite the initial death in March 2025, the company maintained that the benefit-risk profile of the drug remained positive. It was only after a second death occurred in June that Sarepta suspended shipments and paused an ongoing clinical trial.
Kahn Swick & Foti, led by former Louisiana Attorney General Charles C. Foti, Jr., aims to determine if leadership violated federal securities laws by withholding material information. The investigation adds to existing legal pressure, as the company is already defending against an ongoing securities class action lawsuit. Investors seeking to discuss their legal rights or share information regarding the company's disclosures are being encouraged to contact the firm.
Comments (0)
No comments yet. Be the first!